Published in Obesity and Diabetes Week, January 1st, 2007
The private offering was co-led by Channel Medical Partners and Canaan Partners.
"Our investors have recognized the importance of Cylex being first to market with an FDA-approved cellular immune function assay. Cylex has already had an important impact on the treatment of transplant recipients and is becoming a leader in the worldwide multi-billion dollar immune monitoring market," said Judith A. Britz, PhD, chairman and CEO of Cylex. "We have made important strides in advancing ImmuKnow as a standard of care at prestigious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.